2Baker BS, Swain AF, Valdimarsson H, et al. T-cell subpopulations in the blood and skin of patients with psoriasis [J]. Br J Dermatol, 1984, 110(1): 37-44.
6Nickoloff BJ, Wrone-Smith T, Bonish B, et ol. Response of murine and normal human skin to injection of allogeneic bloodderived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94,CD158, and CD161[J]. Arch Dermatol, 1999, 135(5): 546-552.
7Kastelan M, Massari LP, Pasic A, et ol. New trends in the immunopathogenesis of psoriasis [J]. Acta Dermatovenerol Croat,2004, 12(1): 26-29.
8Zarrabeitia MT, Farinas MC, Rodriguez-Valverde V, et aL T and B cell function in psoriasis and psoriatic arthropathy[J]. Allergol Immunopathol (Madr), 1989, 17(3): 155-159.
9Koreck A, Suranyi A, Szony BJ, et al. CD3^+CD56^+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis[J]. Clin Exp Immunol, 2002, 127(1): 176-182.
10Schon M, Denzer D, Kubitza RC, et ol. Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice[J]. J Invest Dermatol, 2000, 114(5): 976-983.
7Iizuka H.Epidermal architecture that depends on turnover time[J].J Dermatol Sci,1995,10(3):220-223.
8Bata-Csorgo Z,Hammmerberg C.Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia[J].J Invest Dermal,1995,105(1 Suppl):89S-94S.
9Casas FC,Jefferies AR.Comparison of intradermal injections of bromodeoxyuridine and tritiated thymidine in the in vivo measurement of epidermal cell turnover time in goats[J].Res Vet Sci,1992,52(1):10-14.
10Halprin KM. Epidermal ''turnover time''-a reexamination[J].Br J Dermatol,1972,86(1):14-19.
4Ksatelan M,Massari LP, Pasic A, et al. New trends in the immunopathogenesis of psoriasis[J]. Acta Dermatovenerol Croat,2004,12:26 - 29.
5Gordon KB, McCormick TS. Evolution of biologic therapies for the treatment of psoriasis[J]. Skinmed,2003,2:286- 294.
6Bata-Csorgo Z, Hammerberg C, Vcorhees JJ, et al. Intral esional T-lymphocyte activation as a mediator of psoriatic epidermal hy-perplasia[ J ]. J Invest Dermal, 1995,105( 1 ) : 89s- 94s.
7Nickoloff BJ ,Schroder JM, Von den Driesch P, et al. Is psoriasis a T-cell disease[J]? Exp Dermatol,2000,9:359 - 75.
8Gilhar A,David M, Ullmann Y, et al. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice[ J ]. Invest Dermatol, 1997,109:283 - 288.
9Cather JC,Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab [ J ]. Expert Opin Biol Ther,2003,3(2) :361 - 370.
10Kess D, Peters T, Zamek J, et al. CD4^+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis[J]. J Immunol, 2003, 171:5697 -5706.
